These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 6701959)

  • 1. Similar activities of IgG1 and IgG2 alloantibodies in enhancement of mouse skin grafts and in opsonization.
    Lems SP; Rijke-Schilder TP; Capel PJ; Koene RA
    Transplantation; 1984 Mar; 37(3):291-6. PubMed ID: 6701959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune regulation by monoclonal antibodies: failure to enhance mouse skin allografts.
    Lems SP; Tax WJ; Capel PJ; Koene RA
    J Immunol; 1983 Jul; 131(1):86-91. PubMed ID: 6345667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of anti-H-2K and H-2D alloantibodies in enhancement and acute antibody-mediated rejection of mouse skin allografts.
    de Waal RM; Capel PJ; Koene RA
    J Immunol; 1980 Feb; 124(2):719-23. PubMed ID: 6985936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of IgG and IgM alloantibodies in the enhancement of mouse skin allografts and the relation with their opsonizing capacity in vivo.
    Lems SP; Tamboer WP; Capel PJ; Koene RA
    J Immunol; 1981 Aug; 127(2):665-9. PubMed ID: 7019328
    [No Abstract]   [Full Text] [Related]  

  • 5. Passive enhancement of mouse skin allografts by alloantibodies is Fc dependent.
    Capel PJ; Tamboer WP; de Waal RM; Jansen JL; Koene RA
    J Immunol; 1979 Feb; 122(2):421-5. PubMed ID: 368240
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation of pure IgG subclasses from mouse alloantiserum and their activity in enhancement and hyperacute rejection of skin allografts.
    Jansen JL; Gerard AP; Kamp J; Tamboer WP; Wijdeveld PG
    J Immunol; 1975 Aug; 115(2):387-91. PubMed ID: 807636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Passive enhancement of mouse tumor allografts by alloantibodies is Fc-dependent.
    de Waal RM; Cornelissen IM; Capel PJ; Koene RA
    J Immunol; 1979 Sep; 123(3):1353-5. PubMed ID: 469254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperacute rejection and enhancement of mouse skin grafts by antibodies with a distinct specificity.
    Jansen JL; Koene RA; Kamp GJ; Hagemann JF; Wijdeveld PG
    J Immunol; 1975 Aug; 115(2):392-4. PubMed ID: 1097512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abrogation of T cell homing by alloantibody.
    Chang AE; Sugarbaker PH
    Transplantation; 1980 Feb; 29(2):127-32. PubMed ID: 6986686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ehancement and hyperacute rejection of skin grafts in the mousefailure to separate cytotoxic and enhancing antibodies from alloantiserum with physicochemical methods.
    Jansen JL; Koene RA; Kamp GJ; Gerlag PG; Wijdeveld PA
    J Immunol; 1975 May; 114(5):1557-62. PubMed ID: 804518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of passive enhancement on graft and host. Graft adaptation by alloantibody as the mechanism of prolonged skin allograft survival.
    McCullough CS; Sugarbaker PH; Matthews W
    Transplantation; 1984 Jan; 37(1):91-6. PubMed ID: 6229914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Procedure for the isolation of mouse anti H-2 antibodies from complex alloantisera.
    De Waal RM; Koene RA
    J Immunol Methods; 1977; 14(3-4):225-9. PubMed ID: 402423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of alloantibodies and suppressor cells in allografted mice treated for passive enhancement.
    Duc HT; Kinsky RG; Monnot P; Voisin GA
    Cell Immunol; 1985 Oct; 95(1):180-94. PubMed ID: 4028170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Passive allograft enhancement by subclasses of polyclonal antibodies directed toward restricted regions of the major histocompatibility complex.
    Duc HT; Kinsky RG; Voisin GA
    Transplantation; 1982 May; 33(5):492-9. PubMed ID: 6806954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative studies on tumor enhancement in mice. I. Enhancement of sarcoma I induced by IgM, IgG1, and IgG2.
    Rubinstein P; Decary F; Streun EW
    J Exp Med; 1974 Aug; 140(2):591-6. PubMed ID: 4846488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention and restoration of second-set liver allograft rejection in presensitized mice: the role of "passenger" leukocytes, donor major histocompatibility complex antigens, and host cytotoxic effector mechanisms.
    Fu F; Li W; Lu L; Thomson AW; Fung JJ; Qian S
    Transplantation; 1999 Feb; 67(3):444-50. PubMed ID: 10030293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of GK1.5 and chimeric rat/mouse GK1.5 anti-CD4 antibodies for prolongation of skin allograft survival and suppression of alloantibody production in mice.
    Rashid A; Auchincloss H; Sharon J
    J Immunol; 1992 Mar; 148(5):1382-8. PubMed ID: 1538121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of growth of allogeneic mouse tumor by the IgG1 fraction of alloantibody preparations.
    Harris TN; Harris S; Henri EM; Farber MB
    J Natl Cancer Inst; 1978 Jan; 60(1):167-72. PubMed ID: 628014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Passive transfer of alloantibodies restores acute cardiac rejection in IgKO mice.
    Wasowska BA; Qian Z; Cangello DL; Behrens E; Van Tran K; Layton J; Sanfilippo F; Baldwin WM
    Transplantation; 2001 Mar; 71(6):727-36. PubMed ID: 11330533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic administration of anti-interleukin-10 antibody prolongs organ allograft survival in normal and presensitized recipients.
    Li W; Fu F; Lu L; Narula SK; Fung JJ; Thomson AW; Qian S
    Transplantation; 1998 Dec; 66(12):1587-96. PubMed ID: 9884244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.